Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers

NAActive, not recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

January 18, 2027

Study Completion Date

January 18, 2028

Conditions
Advanced, Pretreated Solid Tumors
Interventions
PROCEDURE

Biopsy

We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.

Trial Locations (1)

94805

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER